European Medicines Agency has initiated the review of Orion´s dexmedetomidine marketing authorisation application

 

ORION CORPORATION   STOCK EXCHANGE RELEASE  20 October  2010  AT 4.15  PM EET    
        

 

 

 

Orion Corporation has submitted a marketing authorisation application for the intensive care sedative agent dexmedetomidine for the evaluation by the European Medicines Agency (EMA), the pharmaceutical regulatory authority for the EU countries. EMA has announced today that  it has validated the centralised marketing authorisation application and initiated the review. The review time for a centralised marketing authorisation application typically exceeds one year.
                                                                                                                                 
Orion Corporation

 

Timo Lappalainen                       Reijo Salonen
President and CEO                    SVP, Research and Development

 

 

Contact person:
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647

 

 

 

 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi